LAG3 and glioblastoma: In a preclinical mouse model of human GBM, Harris-Bookman and colleagues showed that depletion or inhibition of LAG-3 markedly improved the survival of GBM-bearing mice treated with anti-PD-1 treatment, presumably through increased production of IFN-γ [110].